SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Acosta Andrea

(Last)

(First)

(Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL

94901

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/13/2020

3. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
GVP, Chief Accounting Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,649	D
Common Stock⁽¹⁾	4,380	D
Common Stock⁽²⁾	1,645	D
Common Stock⁽³⁾	1,500	D
Common Stock⁽⁴⁾	2,535	D
Common Stock⁽⁵⁾	3,250	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to buy Common Stock)	03/16/2021⁽⁶⁾	03/15/2030	Common Stock	8,320	73.82	D
Stock Option (Right to buy Common Stock)	07/17/2018⁽⁶⁾	07/16/2027	Common Stock	5,340	86.98	D
Stock Option (Right to buy Common Stock)	03/15/2019⁽⁶⁾	03/14/2028	Common Stock	4,790	83.57	D
Stock Option (Right to buy Common Stock)	03/15/2020⁽⁶⁾	03/14/2029	Common Stock	5,630	94.53	D

Explanation of Responses:

1. Restricted stock units granted on March 16, 2020. Price not applicable.

2. Restricted stock units granted on July 17, 2017. Price not applicable.

3. Restricted stock units granted on March 15, 2018. Price not applicable.

4. Restricted stock units granted on March 15, 2019. Price not applicable.

5. Restricted stock units granted on June 29, 2020. Price not applicable.

6. Option grant vests 12/48th on the date exercisable and 1/48th each month thereafter.

	/s/ Eric Fleekop, Attorney-in-Fact	07/22/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.